Home/Investors/Pontifax

Pontifax

Biotech Investor · 8 portfolio companies

Portfolio

8

Combined Value

$1.5B

Focus Areas

15

Top Stage

Phase 1

Investment Focus

Schizophrenia Bipolar Depression Neuropsychiatric Diseases Fibrosis Immunology & Inflammatory Diseases Metabolic Neurology Cardiovascular Genetic Disorders Metabolic Disease Oncology Infectious Diseases Inflammatory Disorders Immunology Interventional Oncology

Portfolio Companies

Company	Stage	Valuation	Focus
LB Pharmaceuticals	Phase 2	$941.3M	Schizophrenia, Bipolar Depression
Agomab Therapeutics	Phase 1	$554.0M	Fibrosis, Immunology & Inflammatory Diseases
Inversago Pharma	phase-2	—	Metabolic
StrideBio	Phase 1	—	Neurology, Cardiovascular
Carmot Therapeutics	phase-2	—	Metabolic Disease, Oncology
MeMed	commercial	—	Infectious Diseases, Inflammatory Disorders
AryoGen Pharmed	preclinical	—	Oncology, Immunology
IceCure Medical	commercial	—	Oncology, Interventional Oncology

Frequent Co-Investors

OrbiMed1 shared The Column Group1 shared Northpond Ventures1 shared Forbion1 shared RA Capital Management1 shared Novartis Venture Fund1 shared CTI Life Sciences1 shared Amorchem1 shared